The Federal Circuit faulted Ascendis Pharma AS’s maneuver to halt a patent suit in a ruling that effectively allows BioMarin ...

A novel drug for the most common cause of dwarfism accelerated children’s growth in a small but closely watched clinical trial, the company BridgeBio said Monday, advancing the latest treatment in ...

With gene therapy, a cure for growth-hormone resistant dwarfism may be on the horizon. National University of Singapore, Yong Loo Lin School of Medicine Researchers from the NUS Yong Loo Lin School of ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has granted accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide) for the ...

HAMPTON ROADS, Va. - Chandler Crews was born with achondroplasia, a serious, progressive, and lifelong condition that is the most common form of dwarfism. In 2010 at the age of 16, she made the choice ...

(Reuters) - BioMarin Pharmaceutical Inc's once-daily injection for children with the most common type of dwarfism received clearance from the U.S. health regulator on Friday, making it the first ...

Feb 27 (Reuters) - The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's (A71.F), opens new tab once-weekly therapy for children with a rare genetic disorder that causes dwarfism, ...

The Food and Drug Administration approved the first treatment for the most common cause of dwarfism Friday, a drug that has proved to increase children’s height but has been polarizing among adults ...

The FDA will hand down a decision on BioMarin’s rare disease drug vosoritide by Aug. 21 as it says there's no need for an advisory committee. The U.S. regulator has accepted BioMarin’s NDA for ...